RecruitingPhase 1NCT06466395
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias
Studying Acute undifferentiated leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- David McCall, MDM.D. Anderson Cancer Center
- Intervention
- Venetoclax(drug)
- Enrollment
- 22 enrolled
- Eligibility
- 2-21 years · All sexes
- Timeline
- 2025 – 2031
Study locations (1)
- MD Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06466395 on ClinicalTrials.gov